Arcus Biosciences (RCUS) Cash from Financing Activities (2017 - 2026)

Arcus Biosciences' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 97.89% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $349.0 million (up 83.68% YoY), while the FY2025 annual figure was $488.0 million, up 76.17% from the prior year.
• Cash from Financing Activities was $3.0 million for Q1 2026 at Arcus Biosciences, down from $286.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $286.0 million in Q4 2025 to a low of -$2.0 million in Q4 2024.
• Historically, Cash from Financing Activities has averaged $49.1 million across 5 years, with a median of $8.0 million in 2025.
• Biggest YoY gain for Cash from Financing Activities was 22800.0% in 2024; the steepest drop was 166.67% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $11.0 million in 2022, then tumbled by 72.73% to $3.0 million in 2023, then sank by 166.67% to -$2.0 million in 2024, then jumped by 14400.0% to $286.0 million in 2025, then sank by 98.95% to $3.0 million in 2026.
• The last three Cash from Financing Activities figures came in at $3.0 million (Q1 2026), $286.0 million (Q4 2025), and $8.0 million (Q3 2025), per Business Quant data.